Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — November 2025

Genmab — November 2025

Planlagt Fastgjort Låst Flyttet Genmab
176 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • G Offline
    G Offline
    gentogen
    wrote on sidst redigeret af
    #166

    Ret beset ved vi vel ikke noget, men det hedder, at "Overall Survival (OS) is the primary endpoint in USA and in China, with the analysis population including all randomized participants.". Så måske den slags analyser også bare tager længere tid...

    1 Reply Last reply
    0
    • L Offline
      L Offline
      lahn1
      wrote on sidst redigeret af
      #167

      Ja ups, den have jeg lige fået forkert registreret.

      1 Reply Last reply
      0
      • CupcakeC Offline
        CupcakeC Offline
        Cupcake
        wrote on sidst redigeret af
        #168

        25/11 21:02 Euroinvestor "Genmab: Stemningen er vendt - Investoren Helge Larsen sætter ord på udviklingen af Genmab aktien" 2 min https://www.euroinvestor.dk/nyheder/genmab-stemningen-er-vendt

        1 Reply Last reply
        0
        • R Offline
          R Offline
          Raun
          wrote on sidst redigeret af
          #169

          Synes nu mere at den seneste tids "lille" optur er mere et udtryk for stemningen her ændret sig i sektoren,,,, Ser lige at Eli Lilly er steget næsten 100% på 2,5 måned

          1 Reply Last reply
          0
          • N Offline
            N Offline
            NiklasZ
            wrote on sidst redigeret af
            #170

            Det er fuldstændig tosset at se på LLYs stigning, især i
            forhold til Novo.

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #171

              Blood: Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma https://ashpublications.org/blood/article/doi/10.1182/blood.2025029909/547148/Fixed-Duration-Epcoritamab-Plus-R2-Drives https://ashpublications.org/blood/article/146/22/2617/548279/Better-together-epcoritamab-boosts-R2-in-FL

              1 Reply Last reply
              0
              • G Offline
                G Offline
                gentogen
                wrote on sidst redigeret af
                #172

                Impressive: The efficacy appeared impressive: ORR 96% and CR 88% that were maintained even in patients with high-risk features. Minimal residual disease negativity rate was 86%. Survival outcomes at 2 years look favorable as well: remaining in CR for the duration of the study, 82% = KYSO...

                1 Reply Last reply
                0
                • J Offline
                  J Offline
                  JKY_VH
                  wrote on sidst redigeret af
                  #173

                  tak for den gentogen

                  1 Reply Last reply
                  0
                  • J Offline
                    J Offline
                    Jhonnykuskus
                    wrote on sidst redigeret af
                    #174

                    Link Preview Image
                    Ugens grafik: Kinas antibody-udvikling stormer frem

                    Ugens grafik handler om et af de emner, der langsomt men sikkert er på vej frem. Et emne der får mere og mere opmærksomhed

                    favicon

                    Økonomisk Ugebrev (ugebrev.dk)

                    1 Reply Last reply
                    0
                    • J Offline
                      J Offline
                      Jhonnykuskus
                      wrote on sidst redigeret af
                      #175

                      Så vi kan forvente at Kina kommer ind fra højre med mange præperater vi evt. skal konkurrere med

                      1 Reply Last reply
                      0
                      • R Offline
                        R Offline
                        Raun
                        wrote on sidst redigeret af
                        #176

                        Genmab omkring kurs 2090 i US under pæn omsætning 🙂

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #177

                          Donor-Derived T-Cell Redirection With Epcoritamab Achieving Complete Response After Early Post-Allo-HSCT Relapse of DLBCL https://onlinelibrary.wiley.com/doi/10.1002/jha2.70186

                          1 Reply Last reply
                          0

                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                          With your input, this post could be even better 💗

                          Tilmeld Log ind
                          Svar
                          • Svar som emne
                          Login for at svare
                          • Ældste til nyeste
                          • Nyeste til ældste
                          • Most Votes


                          • Log ind

                          • Har du ikke en konto? Tilmeld

                          • Login or register to search.
                          Powered by NodeBB Contributors
                          • First post
                            Last post
                          0
                          • Kategorier
                          • Seneste
                          • Etiketter
                          • Populære
                          • Verden
                          • Bruger
                          • Grupper